Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sygnis Pharma has received a positive recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency for AX200, for the treatment of amyotrophic lateral sclerosis or ALS.
Subscribe to our email newsletter
The European Medicines Agency (EMEA) orphan drug designation program is dedicated to stimulate and support the development of pharmaceuticals to treat life-threatening or very serious and rare diseases, which cannot be treated or can only be treated insufficiently.
Alfred Bach, CEO of Sygnis Pharma, said: “We will plan further steps in close cooperation with EMEA and hope to initiate clinical trials within the next twelve months.”